Physician profile
Patrick J Proffer
NPI 1952399206
$1,253.32
in general payments reported to CMS, 2019-2025
15 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2021: $62.54 · 2022: $325 · 2023: $145 · 2024: $139 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $293.54 | 2024-2025 | Daxxify |
| Davol INC. | $178.60 | 2022 | |
| Abbvie INC. | $127.51 | 2025 | |
| Stryker Corporation | $119.98 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $118.63 | 2025 | Iovera, Exparel |
| Sientra, INC. | $108.80 | 2021-2022 | |
| Ethicon US, LLC | $68.24 | 2023 | Dermabond Prineo, Megadyne |
| Tepha INC | $61.59 | 2019 | |
| Lifenet Health | $47.35 | 2023 | |
| Galderma Laboratories, L.P. | $40.69 | 2022 | |
| Mentor Worldwide LLC | $29.40 | 2023 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Horizon Therapeutics Plc | $23.78 | 2021 | |
| Bioventus LLC | $18.83 | 2022 | |
| Baudax Bio INC. | $16.38 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$749,928.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Proffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.